Toggle light / dark theme

Gene Therapy for Parkinson’s Disease Associated with GBA1 Mutations

Abeliovich et al. make a compelling case for the promise of using gene therapy to treat Parkinson’s disease (PD) patients who possess mutations in the GBA1 gene. People interested in the clinical-translational side of biomedicine should definitely check this out!


This website uses a security service to protect against malicious bots. This page is displayed while the website verifies you are not a bot.

Dyno Therapeutics Launches Two New AAV Capsids and AI Platform for Rare Disease Therapeutic Development at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Dyno continues to develop impressive new AAV capsids with their AI-guided design approach!


About Dyno Therapeutics.

Dyno Therapeutics is on a mission to build high-performance genetic technologies that transform patients’ lives. Dyno applies AI to build technologies for gene delivery and sequence design that advance “Genetic Agency” — an individual’s ability to take action at the genetic level to live a healthier life — through safe, effective and widely accessible genetic treatments. With frontier AI models and high-throughput in vivo experimentation, Dyno designs optimized AAV delivery vectors that solve gene delivery challenges across a wide range of therapeutic applications including eye, muscle and CNS. Dyno partners across industries to ensure these life-transforming technologies can help as many patients as possible, including through strategic collaborations with leading gene therapy developers Astellas and Roche and with technology companies including NVIDIA. Dyno’s AI-designed capsids are available for direct licensing and through the Dyno Frontiers Network. Visit www.dynotx.com for more information.

‘Dyno Therapeutics’, ‘dyno’, the Dyno logo, and mountain logo are registered trademarks of Dyno Therapeutics, Inc. All rights reserved.

Engineered proteins store digital files with 30 times density at one-tenth cost

Massive volumes of digital data are generated every day from AI training, big data analytics and smart devices. As conventional hard drives and cloud storage are increasingly constrained by high costs, limited capacity, high power consumption and short lifespans, molecular data storage has emerged as a breakthrough storage alternative.

Researchers at The Hong Kong Polytechnic University (PolyU) have pioneered a method that uses engineered proteins to store digital data and, for the first time, completed the full process from data storage to data retrieval in de novo designed unnatural proteins.

This demonstrates the potential of establishing a protein-based storage framework with sustainability, high storage capacity and high stability, offering a promising solution to the explosive AI-generated growth in data globally.

TeamPCP hackers advertise Mistral AI code repos for sale

The TeamPCP hacker group is threatening to leak source code from the Mistral AI project unless a buyer is found for the data.

In a post on a hacker forum, the threat actor is asking $25,000 for a set of nearly 450 repositories.

Mistral AI is a French artificial intelligence company founded by former researchers from Google’s DeepMind and Meta, which provides open-weight large language models (LLMs), both open source and proprietary.

OpenAI confirms security breach in TanStack supply chain attack

OpenAI says two employees’ devices were breached in the recent TanStack supply chain attack that impacted hundreds of npm and PyPI packages, causing the company to rotate code-signing certificates for its applications as a precaution.

In a security advisory published today, the company said the incident did not impact customer data, production systems, intellectual property, or deployed software.

The company says the breach is linked to the recent “Mini Shai-Hulud” supply-chain campaign by the TeamPCP extortion gang, which targeted developers by slipping malicious updates into trusted and popular software packages.

Cost-Effectiveness of Thrombectomy With or Without Alteplase in Large Vessel Occlusion StrokeA Meta-Analysis Considering Time-to-Treatment

This website uses a security service to protect against malicious bots. This page is displayed while the website verifies you are not a bot.

/* */